grazoprevir
Sign in to saveAlso known as grazoprevir anhydrous, MK-5172
Grazoprevir is a drug approved for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS5A replication complex inhibitor elbasvir under the trade name Zepatier, either with or without ribavirin.
Research
464 papers- Grazoprevir.2006
- Elbasvir/grazoprevir.Australian prescriber · 2017
- Grazoprevir/elbasvir combination therapy for HCV infection.Therapeutic advances in gastroenterology · 2017
- Elbasvir and grazoprevir for the treatment of hepatitis C.Expert review of anti-infective therapy · 2021
- Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.Drugs · 2017
via PubMed
~4 min read
Encyclopedic overview
6 sectionsContents
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- References
{{Drugbox | IUPAC_name = (1R,18R,20R,24S,27S)-N-{(1R,2S)-1-[(Cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.03,12.05,10.0 18,20]nonacosa-3,5,7,9,11-pentaene-27-carboxamide | image = Grazoprevir.svg | image_class = skin-invert-image
| tradename = Zepatier (combination with elbasvir) | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral
Excerpted from Wikipedia’s “grazoprevir” article, available under the CC BY-SA 4.0 licence.